Vincenzo Picardi

Vincenzo Picardi

Auto-generated profile, based on publicly available information

Vincenzo Picardi

Department of Radiotherapy, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Campobasso, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2009 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti
Mariangela MassaccesiMariangela Massaccesi
Mariangela Massaccesi
Giuseppe La TorreGiuseppe La Torre
Giuseppe La Torre
Luciana CaravattaLuciana Caravatta
Luciana Caravatta
APAdele Piscopo
Adele Piscopo
VVVincenzo Valentini
Vincenzo Valentini

1 July 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
VPVincenzo Picardi
Vincenzo Picardi
FDFrancesco Deodato
Francesco Deodato
AGAlessandra Guido
Alessandra Guido
LGLucia Giaccherini
Lucia Giaccherini
Gabriella MacchiaGabriella Macchia
Gabriella Macchia
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti

1 May 2012 in Clinical Oncology
Verified
Journal Article
Closed access
SCS. Cilla
S. Cilla
Luciana CaravattaLuciana Caravatta
Luciana Caravatta
VPV. Picardi
V. Picardi
DSD. Sabatino
D. Sabatino
Gabriella MacchiaGabriella Macchia
Gabriella Macchia
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti

12 June 2012 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
Luciana CaravattaLuciana Caravatta
Luciana Caravatta
GSGiuseppina Sallustio
Giuseppina Sallustio
FPFabio Pacelli
Fabio Pacelli
GPGilbert DA Padula
Gilbert DA Padula
FDFrancesco Deodato
Francesco Deodato
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti
Background: Radiotherapy (RT) is widely used in the treatment of pancreatic cancer. Currently, recommendation has been given for the delineation of the clinical target volume (CTV) in adjuvant RT. Based on recently reviewed pathologic data, the aim of this study is to propose criteria for the CTV definition and delineation including elective nodal irradiation (ENI) in the preoperative and definitive treatment of pancreatic cancer. Methods: The anatomical structures of interest, as well as the abdominal vasculature were identified on intravenous contrast-enhanced CT scans of two different patients with pancreatic cancer of the head and the body. To delineate the lymph node area, a margin of 10 mm was added to the arteries. Results: We proposed a set of guidelines for elective treatment of high-risk nodal areas and CTV delineation. Reference CT images were provided. Conclusions: The proposed guidelines could be used for preoperative or definitive RT for carcinoma of the head and body of the pancreas. Further clinical investigations are needed to validate the defined CTVs.

1 January 2014 in Medical Dosimetry
Verified
Journal Article
Closed access
Savino CillaSavino Cilla
Savino Cilla
FDFrancesco Deodato
Francesco Deodato
CDCinzia Digesù
Cinzia Digesù
Gabriella MacchiaGabriella Macchia
Gabriella Macchia
VPVincenzo Picardi
Vincenzo Picardi
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti

2 February 2012 in Cancer Investigation
Verified
Journal Article
Closed access
Gabriella MacchiaGabriella Macchia
Gabriella Macchia
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti
SCSavino Cilla
Savino Cilla
Edy IppolitoEdy Ippolito
Edy Ippolito
Mariangela MassaccesiMariangela Massaccesi
Mariangela Massaccesi
FDFrancesco Deodato
Francesco Deodato
To analyze the results of extracranial stereotactic radiotherapy (ESRT) experience in pancreatic cancer patients. Four noncoplanar fixed beams were used in all patients. Analysis of 16 patients was carried out. Overall response rate was 56.2%. Fifteen patients experienced local and/or distant progression of disease (median follow-up: 24 months). Two-year local progression-free, distant progression-free, and overall survivals were 85.7%, 58.7%, and 50.0%, respectively. Toxicity was less than grade 2 in all, although 1 patient had severe duodenal bleeding. Quality of life scores were unchanged. ESRT was associated with low complication rate, and not worsening the patients' quality of life.